What type of study is this?

Rituximab Treatment in Lupus Nephritis Resistant to Conventional Therapy: A Single-Centre Experience

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows improved outcomes in lupus nephritis patients after rituximab treatment, suggesting its efficacy and safety.

Rituximab significantly reduced proteinuria to 747mg/day, improving outcomes in lupus nephritis patients.
At the primary endpoint, 53.1% of patients achieved a prednisolone dose of 5mg after treatment with rituximab.
SLEDAI-2K scores declined significantly from 16.3 to 7.2, indicating reduced disease activity in treated patients.
The median steroid dose was reduced from 24.13mg to 7.5mg/day, highlighting rituximab’s potential for therapy-resistant cases.

Şentürk et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark